1h Free Analyst Time
The red biotechnology market is forecasted to grow by USD 174.56 billion during 2023-2028, accelerating at a CAGR of 6.23% during the forecast period. The report on the red biotechnology market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advancements in genomic research, an increase in the prevalence of chronic diseases, and a growing aging population globally.
The red biotechnology market is segmented as below:
By Product
- Monoclonal antibodies
- Gene therapy
- Polyclonal antibodies
- Cell-based immunotherapy products
- Others
By End-user
- Pharmaceutical and biotechnology companies
- CMOs and CROs
- Academic research institutes
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the red biotechnology market covers the following areas:
- Red biotechnology market sizing
- Red biotechnology market forecast
- Red biotechnology market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape and an analysis of the key vendors.
The publisher presents a detailed picture of the market through study, synthesis, and summation of data from multiple sources by analyzing key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The analyst recognizes the following companies as the key players in the global red biotechnology market: Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Bruker Corp., CRISPR Therapeutics AG, Editas Medicine Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Merck KGaA, Mesoblast Ltd., Moderna Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., STEMCELL Technologies Inc., and Teva Pharmaceutical Industries Ltd.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is rising stem cell research and therapies.'
According to the report, one of the major drivers for this market is the advancements in genomic research.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape and a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Bruker Corp.
- CRISPR Therapeutics AG
- Editas Medicine Inc.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- Merck KGaA
- Mesoblast Ltd.
- Moderna Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- STEMCELL Technologies Inc.
- Teva Pharmaceutical Industries Ltd.
